natgillin/translations-raw huggingface dataset:
This veterinary medicinal product does not require any special storage conditions. 
Ovaj veterinarsko medicinski proizvod ne zahtijeva posebne uvjete čuvanja.
Each chewable tablet contains: Afoxolaner MERIAL 
Svaka tableta za žvakanje sadrži: Afoksolaner MERIAL
In-vitro experiments demonstrated that P-glycoprotein efflux does not occur, confirming that afoxolaner is not a substrate for the P-glycoprotein transporters. 
In-vitro eksperimenti pokazali su da se efluks vezan uz P-glikoprotein ne događa, čime je potvrđeno da afoksolaner nije supstrat za P-glikoproteinske transportere.
The periodic safety update report (PSUR) submissions shall be synchronised and submitted at the same frequency as for the reference product. 
Periodička izvješća o neškodljivosti lijeka (PSUR) moraju se uskladiti i dostaviti u istim vremenskim periodima kao i za referentni proizvod.
The mean maximum concentration (Cmax) was 1,655 ± 332 ng/ml in plasma at 2-4 hours (Tmax) after a 2.5 mg/kg afoxolaner dose. 
Srednja maksimalna koncentracija (Cmax) je 1,655 ± 332 ng/ml u plazmi 2-4 sata (Tmax) nakon 2,5 mg/kg afoksolaner doze.
Soy protein fines Braised beef flavouring Povidone (E1201) Macrogol 400 
Aroma pirjane govedine Povidon (E1201) Makrogol 400
Afoxolaner in the dog is metabolised to more hydrophilic compounds and then eliminated. 
Afoksolaner u psa se metabolizira u više hidrofilnih spojeva, a zatim eliminira.
In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 2 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. 
U nedostatku dostupnih podataka, liječenje štenadi mlađih od 8 tjedna i/ili pasa lakših od 2 kg tjelesne težine treba temeljiti na procjeni koristi i rizika odgovornog veterinara.
Laboratory studies in rats and rabbits have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females. 
Laboratorijska ispitivanja na štakorima i kunićima nisu dala dokaz teratogenog učinka ili bilo kakav nepovoljan učinak na reproduktivnu sposobnost mužjaka i ženki.
1 tablet 3 tablets 6 tablets 15 tablets 
6 tableta 15 tableta
For dogs above 50 kg bodyweight, use an appropriate combination of chewable tablets of different/same strengths. 
Za pse iznad 50 kg tjelesne težine, koristiti odgovarajuće kombinacije žvakaćih tableta različite/iste jačine.
Further monthly administration of the product may be required based on clinical assessment and skin scrapings. 
Dodatne mjesečne primjene proizvoda moguće je preporučiti na temelju kliničkog pregleda i pretrage strugotina kože.
Afoxolaner is an insecticide and acaricide belonging to the isoxazoline family. 
Afoksolaner je insekticid i akaricid koji pripada skupini izoksazolina.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carton 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU Kartonska kutija
Macrogol 15 hydroxystearate Glycerol (E422) Medium-chain triglycerides 
Makrogol 15 hidroksistearat Glicerol (E422) Trigliceridi srednjeg lanca
Monthly intervals throughout the flea and/or tick seasons, based on local epidemiological situations. 
Mjesečnim intervalima tijekom sezone buha i/ili krpelja, na temelju lokalnih epidemioloških situacija.
Treatment of flea infestation in dogs (Ctenocephalides felis and C. canis) for at least 5 weeks. 
Liječenje infestacije buhama u pasa (Ctenocephalides felis i C. canis) do najmanje 5 tjedana.
Overdose (symptoms, emergency procedures, antidotes): 
Predoziranje (simptomi, postupci u slučaju nužde, protuotrov):
Afoxolaner acts at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. 
Afoksolaner djeluje na ligandom regulirane kloridne kanale, osobito one s neurotransmiterom gama-aminomaslačnom kiselinom (GABA), čime blokira pre i post-sinaptički prijenos kloridnih iona kroz stanične membrane.
Special precautions for use in animals: 
Posebne mjere opreza za uporabu na životinjama:
Treatment of demodicosis (caused by Demodex canis). 
Liječenje demodikoze (uzrokovane s Demodex canis).
Shelf life of the veterinary medicinal product as packaged for sale: 3 years. 
Rok trajanja kad je zapakiran za prodaju: 3 godine.
Parasites need to start feeding on the host to become exposed to afoxolaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded. 
Parazit mora započeti hranjenje na domaćinu kako bi započelo djelovanje afoksolanera, stoga se rizik od prijenosa krpeljno prenosivih bolesti ne može u potpunosti isključiti.
After oral administration in dogs, afoxolaner was shown to have high systemic absorption following administration. 
Nakon peroralne primjene kod pasa, afoksolaner je pokazao da ima visoku sustavnu apsorpciju nakon primjene.
Afoxolaner (mg) 
Afoksolaner (mg)
The selective toxicity of afoxolaner between insect/acarines and mammals may be inferred by the differential sensitivity of the insect/acarines' GABA receptors versus mammalian receptors. 
Selektivna toksičnost afoksolanera za kukce/akaride i sisavce se može zaključiti po različitoj osjetljivosti GABA receptora insekata/akarida u odnosu na receptore sisavaca.
Pharmacotherapeutic group: Ectoparasiticides for systemic use. 
Farmakoterapijska skupina: ostali ektoparazitici za sustavnu primjenu.
One carton contains one blister of 1, 3 or 6 chewable tablets or 15 blisters of 1 chewable tablet. 
Jedna kartonska kutija sadrži blister s 1, 3, ili 6 tableta ili 15 blistera s 1 tabletom za žvakanje.
No adverse reactions were observed in healthy Beagle puppies over 8 weeks of age when treated with 5 times the maximum dose repeated 6 times at intervals of two to four weeks. 
Nepovoljne reakcije nisu zabilježene kod zdravih beagle štenaca u dobi od 8 tjedana, kada se tretira s dozom pet puta većom od maksimalne doze, ponovljeno 6 puta u intervalima od 2 - 4 tjedana.
Mild gastrointestinal effects (vomiting, diarrhoea), pruritus, lethargy, anorexia, and neurological signs (convulsions, ataxia and muscle tremors) have been reported very rarely. 
Blage nuspojave vezane uz gastrointestinalni sustav (povraćanje, proljev), pruritus, letargija, anoreksija i neurološki simptomi (konvulzije, ataksija i mišićni tremor) prijavljivane su vrlo rijetko.
The metabolites and parent compound are eliminated from the body via urinary and biliary excretion with the majority eliminated in the bile. 
Metaboliti i matični spoj se eliminiraju iz tijela putem mokraće te bilijarnim izlučivanjem, s većom eliminacijom putem žuči.
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). 
Može se koristiti kao dio strategije liječenja za kontrolu alergijskog dermatitisa uzrokovanog buhama (FAD).
D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
OSTALI UVJETI I ZAHTJEVI ZA ODOBRENJE STAVLJANJA U PROMET
Do not use in cases of hypersensitivity to the active substance or to any of the excipients. 
Ne koristiti u slučajevima preosjetljivosti na djelatnu tvar ili na bilo koju od pomoćnih tvari.
Afoxolaner distributes into tissues with a volume of distribution of 2.6 ± 0.6 l/kg and a systemic clearance value of 5.0 ± 1.2 ml/hr/kg. 
Afoksolaner se distribuira u tkiva s volumenom raspodjele koji iznosi 2,6 ± 0,6 l/kg te sustavnim klirensom vrijednosti 5,0 ± 1,2 ml/h/kg.
Maize starch 
Kukuruzni škrob
Veterinary medicinal product subject to prescription. 
Veterinarsko medicinski proizvod izdaje se na recept.
Afoxolaner MERIAL 
Afoksolaner MERIAL
Afoxolaner MERIAL tablets are chewable and palatable to most dogs. 
Afoksolaner MERIAL tablete za žvakanje ukusne su za većinu pasa.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. 
Krpelji i buhe se moraju pričvrstiti na domaćina kako bi bili izloženi djelovanju djelatne tvari.
• very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
- vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
Special precautions to be taken by the person administering the veterinary medicinal product to animals To prevent children from getting access to the veterinary medicinal product, remove only one chewable tablet at a time from the blister. 
Posebne mjere koje treba poduzeti osoba koja propisuje veterinarsko-medicinski proizvod Kako bi djeci spriječili pristup veterinarsko-medicinskom proizvodu, izvadite samo jednu tabletu za žvakanje u isto vrijeme iz blistera.
Marketing authorisation holder: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein GERMANY 
Nositelj odobrenja za stavljanje u promet Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
Treatment of tick infestation in dogs (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus). 
Liječenje invazije krpelja u pasa (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus).
Afoxolaner MERIAL is active against adult fleas as well as several tick species such as Dermacentor reticulatus and D. variabilis, Ixodes ricinus and I. scapularis, Rhipicephalus sanguineus, Amblyomma americanum, and Haemaphysalis longicornis. 
Afoksolaner MERIAL djeluje protiv odraslih buha kao i na nekoliko vrsta krpelja poput Dermacentor reticulatus, D. variabilis, Ixodes ricinus i I. scapularis, Rhipicephalus sanguineus, Amblyomma americanum i Haemaphysalis longicornis.
Severe cases may require prolonged monthly treatments. 
U težim slučajevima liječenje produljiti u mjesečnim intervalima.
The tablets are chewable and palatable to most dogs. 
Način primjene: Tablete za žvakanje ukusne su za većinu pasa.
• very common (more than 1 in 10 animals treated displaying adverse reaction(s)) 
- vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu (e))
Chewable tablets 
Tablete za žvakanje
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis). 
Liječenje Sarcoptes-šuge (uzrokovane s Sarcoptes scabiei var.canis).
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis): 
Liječenje Sarcoptes-šuge (uzrokovane sa Sarcoptes scabiei var.canis).
For oral use 
Za peroralnu primjenu
Dogs 2-4 kg Dogs >4-10 kg Dogs >10-25 kg Dogs >25-50 kg 
Psi od 2-4 kg Psi >4-10 kg Psi >10-25 kg Psi >25-50 kg
Monthly administration of the product until two negative skin scrapings are obtained one month apart. 
Liječenje demodikoze (uzrokovane s Demodex canis) Mjesečna primjena proizvoda sve do pojave dva negativna nalaza dobivena pretragom strugotina kože uzetih u razmaku od mjesec dana.
Most reported adverse reactions were self-limiting and of short duration. 
Većina nuspojava kratko traje i općenito prolaze same od sebe.
• rare (more than 1 but less than 10 animals in 10,000 animals treated) 
- rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja)
Afoxolaner MERIAL 136 mg 
Afoksolaner MERIAL 136 mg
Treatment of flea and tick infestations: 
Liječenje infestacije buhama i krpeljima
Afoxolaner MERIAL 68 mg 
Afoksolaner MERIAL 68 mg
Mottled red to reddish brown, circular shaped (tablets for dogs 2-4 kg) or rectangular shaped (tablets for dogs >4-10 kg, tablets for dogs >10-25 kg and tablets for dogs >25-50 kg). 
Prošarane crvene do smeđe crvenkaste, kružnog (tablete za pse 2-4 kg) ili pravokutnog oblika (tablete za pse >4-10 kg, tablete za pse >10-25 kg i tablete za pse >25-50 kg).
Afoxolaner MERIAL 28 mg 
Afoksolaner MERIAL 28 mg
Afoxolaner MERIAL 11 mg 
Afoksolaner MERIAL 11 mg
chewable tablets for dogs 2-4 kg chewable tablets for dogs >4-10 kg chewable tablets for dogs >10-25 kg chewable tablets for dogs >25-50 kg 
tablete za žvakanje za pse 2-4 kg tablete za žvakanje za pse >4-10 kg tablete za žvakanje za pse >10-25 kg tablete za žvakanje za pse >25-50 kg
common (more than 1 but less than 10 animals in 100 animals treated) uncommon (more than 1 but less than 10 animals in 1,000 animals treated) rare (more than 1 but less than 10 animals in 10,000 animals treated) very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
- česte ( više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje 10 životinja na 1.000 tretiranih životinja)
Afoxolaner is active against adult fleas as well as several tick species such as Dermacentor reticulatus and D. variabilis, Ixodes ricinus and I. scapularis, Rhipicephalus sanguineus, Amblyomma americanum and Haemaphysalis longicornis. 
D. variabilis, Ixodes ricinus I. scapularis, Rhipicephalus sanguineus, Amblyomma americanum, Haemaphysalis longicornis.
Name and address of the manufacturer responsible for batch release 
PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE Naziv i adresa proizvođača odgovornog za puštanje serije u promet
The frequency of adverse reactions is defined using the following convention: 
Učestalost nuspojava je određena sljedećim pravilima:
The frequency of adverse reactions is defined using the following convention: very common (more than 1 in 10 animals treated displaying adverse reaction(s)). 
Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e)) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja)
Afoxolaner MERIAL 11 mg dogs 2-4 kg Afoxolaner MERIAL 28 mg dogs >4-10 kg Afoxolaner MERIAL 68 mg dogs >10-25 kg Afoxolaner MERIAL 136 mg dogs >25-50 kg afoxolaner 
Afoksolaner MERIAL 11 mg psi 2-4 kg Afoksolaner MERIAL 28 mg psi >4-10 kg Afoksolaner MERIAL 68 mg psi >10-25 kg Afoksolaner MERIAL 136 mg psi >25-50 kg afoxolaner
Afoxolaner MERIAL 11 mg chewable tablets for dogs (2-4 kg) Afoxolaner MERIAL 28 mg chewable tablets for dogs (>4-10 kg) Afoxolaner MERIAL 68 mg chewable tablets for dogs (>10-25 kg) Afoxolaner MERIAL 136 mg chewable tablets for dogs (>25-50 kg) afoxolaner 
Afoksolaner MERIAL 11 mg tableta za žvakanje za pse (2-4 kg) Afoksolaner MERIAL 28 mg tableta za žvakanje za pse (>4-10 kg) Afoksolaner MERIAL 68 mg tableta za žvakanje za pse (>10-25 kg) Afoksolaner MERIAL 136 mg tableta za žvakanje za pse (>25-50 kg) afoksolaner
Afoxolaner MERIAL 11 mg chewable tablets for dogs 2-4 kg Afoxolaner MERIAL 28 mg chewable tablets for dogs >4-10 kg Afoxolaner MERIAL 68 mg chewable tablets for dogs >10-25 kg Afoxolaner MERIAL 136 mg chewable tablets for dogs >25-50 kg afoxolaner 
Afoksolaner MERIAL 11 mg tablete za žvakanje za pse od 2-4 kg Afoksolaner MERIAL 28 mg tablete za žvakanje za pse >4-10 kg Afoksolaner MERIAL 68 mg tablete za žvakanje za pse >10-25 kg Afoksolaner MERIAL 136 mg tablete za žvakanje za pse >25-50 kg afoxolaner
PACKAGE LEAFLET: Afoxolaner MERIAL 11 mg chewable tablets for dogs 2-4 kg Afoxolaner MERIAL 28 mg chewable tablets for dogs >4-10 kg Afoxolaner MERIAL 68 mg chewable tablets for dogs >10-25 kg Afoxolaner MERIAL 136 mg chewable tablets for dogs >25-50 kg 
UPUTA O VMP : Afoksolaner MERIAL 11 mg tableta za žvakanje za pse 2-4 kg Afoksolaner MERIAL 28 mg tableta za žvakanje za pse >4-10 kg Afoksolaner MERIAL 68 mg tableta za žvakanje za pse >10-25 kg Afoksolaner MERIAL 136 mg tableta za žvakanje za pse >25-50 kg
Afoxolaner MERIAL 11 mg chewable tablets for dogs 2-4 kg Afoxolaner MERIAL 28 mg chewable tablets for dogs >4-10 kg Afoxolaner MERIAL 68 mg chewable tablets for dogs >10-25 kg Afoxolaner MERIAL 136 mg chewable tablets for dogs >25-50 kg 
Afoksolaner MERIAL 11 mg tablete za žvakanje za pse 2-4 kg Afoksolaner MERIAL 28 mg tablete za žvakanje za pse >4-10 kg Afoksolaner MERIAL 68 mg tablete za žvakanje za pse >10-25 kg Afoksolaner MERIAL136 mg tablete za žvakanje za pse >25-50 kg
The patient should take one tablet once a day. 
Bolesnik treba uzimati jednu tabletu jedanput dnevno.
In both studies there were no cases of resistance to treatment after 48 weeks. 
U obama ispitivanjima nije bilo slučajeva rezistencije na liječenje nakon 48 tjedana.
What is Dovato and what is it used for? 
Što je Dovato i za što se koristi?
What measures are being taken to ensure the safe and effective use of Dovato? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Dovato?
Dovato (dolutegravir / lamivudine) 
Dovato (dolutegravir/lamivudin)
Other information about Dovato 
Ostale informacije o lijeku Dovato
Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1) in adults and adolescents over 12 years old who weigh at least 40 kg. 
Dovato je lijek za liječenje infekcije virusom humane imunodeficijencije tipa 1 (HIV-1) u odraslih i adolescenata starijih od 12 godina i tjelesne težine od najmanje 40 kg.
In these studies, 91% of patients with HIV-1 who took the Dovato combination no longer had detectable levels of HIV (below 50 copies per ml) after 48 week compared with 93% of those who were taking the triple combination. 
U tim ispitivanjima 91 % bolesnika zaraženih virusom HIV-1 koji su uzimali kombinaciju lijeka Dovato više nije imalo značajne razine virusa HIV (ispod 50 kopija po ml) nakon 48 tjedana, u usporedbi s 93 % onih koji su uzimali trostruku kombinaciju.
What are the risks associated with Dovato? 
Koji su rizici povezani s lijekom Dovato?
Both active substances have already been authorised in the European Union as separate tablets: dolutegravir in 2014 and lamivudine in 1996. 
Obje djelatne tvari već su odobrene u Europskoj uniji u obliku zasebnih tablete: dolutegravir u 2014., a lamivudin u 1996.
Dovato is available as tablets containing 50 mg of dolutegravir and 300 mg of lamivudine. 
Dovato je dostupan u obliku tableta od 50 mg dolutegravira i 300 mg lamivudina.
Dovato (dolutegravir / lamivudine) EMA/276259/2019 
Dovato (dolutegravir/lamivudin) EMA/276259/2019
Dovato does not cure HIV infection or AIDS, but it may hold off damage to the immune system and the development of infections and diseases associated with AIDS. 
Dovato ne liječi infekciju HIV-om ni AIDS, ali može odgoditi oštećenje imunosnog sustava te razvoj infekcija i bolesti povezanih s AIDS-om.
Why is Dovato authorised in the EU? 
Zašto je lijek Dovato odobren u EU-u?
Side effects reported with Dovato are carefully evaluated and any necessary action taken to protect patients. 
Nuspojave prijavljene za lijek Dovato pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
An overview of Dovato and why it is authorised in the EU 
Pregled informacija o lijeku Dovato i zašto je odobren u EU-u
Triple combination therapy is used for HIV treatment to reduce the chance of the virus becoming resistant to treatment. 
Trostruka kombinirana terapija primjenjuje se za liječenje infekcije HIV-om kako bi se smanjili izgledi da virus postane otporan na liječenje.
As for all medicines, data on the use of Dovato are continuously monitored. 
Kao i za sve lijekove, podatci o primjeni lijeka Dovato kontinuirano se prate.
Dolutegravir stops the activity of an enzyme called integrase (and is known as an integrase inhibitor), while lamivudine stops the activity of reverse transcriptase (and is known as a nucleoside reverse transcriptase inhibitor or NRTI). 
Dolutegravir zaustavlja djelovanje enzima koji se naziva integraza (a poznat je kao inhibitor integraze), a lamivudin zaustavlja djelovanje reverzne transkriptaze (i poznat je kao nukleozidni inhibitor reverzne transkriptaze ili NRTI).
The most common serious side effects (which may affect up to 1 in 100 people) are allergic reactions, including rash and severe liver problems. 
Najčešće ozbiljne nuspojave (koje se mogu javiti u više od 1 na 100 osoba) jesu alergijske reakcije, uključujući osip i teške probleme s jetrom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dovato have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Dovato nalaze se u sažetku opisa svojstava i u uputi o lijeku.
For more information about using Dovato, see the package leaflet or contact your doctor or pharmacist. 
Za više informacija o primjeni lijeka Dovato pročitajte uputu o lijeku, odnosno obratite se liječniku ili ljekarniku.
The most common side effects with Dovato (which may affect up to 1 in 10 people) are headache, diarrhoea, nausea and difficulty sleeping. 
Najčešće nuspojave lijeka Dovato (koje se mogu javiti u više od 1 na 10 osoba) jesu glavobolja, proljev, mučnina i otežano spavanje.
The two active substances in Dovato, dolutegravir and lamivudine, block the activity of enzymes that the virus uses to make new copies of itself. 
Dvije djelatne tvari lijeka Dovato, dolutegravir i lamivudin, inhibiraju djelovanje enzima koje virus upotrebljava za stvaranje novih vlastitih kopija.
Dovato can only be obtained with a prescription and should be prescribed by a doctor who is experienced in managing HIV infection. 
Lijek Dovato izdaje se samo na recept, a treba ga propisati liječnik s iskustvom u liječenju infekcije HIV-om.
Dovato received a marketing authorisation valid throughout the EU on 1 July 2019 Further information on Dovato can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/dovato This overview was last updated in 08-2019. 
Više informacija o lijeku Dovato dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/dovato
Two main studies, involving 1,441 patients, have shown that the combination of the two active substances in Dovato is as effective at lowering the amount of HIV in the blood as a triple combination therapy (dolutegravir plus tenofovir plus emtricitabine). 
U dvama glavnim ispitivanjima, koja su obuhvatila 1 433 bolesnika, kombinacija dviju djelatnih tvari u lijeku Dovato pokazala se jednako učinkovitom u smanjenju količine HIV-a u krvi kao i terapija trostrukom kombiniranom terapijom (dolutegravir i tenofovir i emtricitabin).
This medicine contains the active substances dolutegravir and lamivudine and is used to treat infections that are not resistant to medicines of the same class as dolutegravir or to lamivudine. 
Ovaj lijek sadrži djelatne tvari dolutegravir i lamivudin te se primjenjuje za liječenje infekcija koje nisu otporne na lijekove istog razreda kao dolutegravir i lamivudin.
In two main studies, the Dovato combination was just as effective as a triple combination in patients with HIV-1, with no cases of resistance developing in these patients. 
Dovato bila je jednako učinkovita kao trostruka kombinacija u bolesnika s virusom HIV-1, pri čemu u tih bolesnika nije došlo do pojave rezistencije.
How does Dovato work? 
Kako djeluje Dovato?
What benefits of Dovato have been shown in studies? 
Koje su koristi od lijeka Dovato utvrđene u ispitivanjima?
How is Dovato used? 
Kako se Dovato primjenjuje?
Furthermore, both active substances are available in a single tablet and are acceptably safe.The European Medicines Agency therefore decided that Dovato's benefits are greater than its risks and that it can be authorised for use in the EU. 
Europska agencija za lijekove stoga je odlučila da koristi od lijeka Dovato nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
3 (3x1) inhalers (360(3x120) actuations) (multipack) 
3 (3x1) inhalatora (360 (3x120) potisaka) (višestruko pakiranje)
1 inhaler (120 actuations) 
1 inhalator (120 potisaka)
Pack size 
Jačina
Uncontrollable excessive shopping or spending. 
Nekontrolirano prekomjerno kupovanje ili trošenje.
There is no specific antidote. 
Nema specifičnog antidota.
Take the next dose normally, when it is time to take it. 
Uzmite sljedeću dozu kako je uobičajeno, kada je vrijeme da je uzmete.
You should speak with your doctor about any suspicious skin changes. 
Morate razgovarati sa svojim liječnikom o svakoj sumnjivoj promjeni na koži.
Your doctor may need to adjust or stop your dose. 
Vaš liječnik će možda morati prilagoditi dozu ili prekinuti liječenje.
Strong impulse to gamble excessively despite serious personal or family consequences. 
Jak nagon za pretjeranim kockanjem unatoč ozbiljnim posljedicama po njih ili obitelj.